What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now?

Spruce Biosciences (SPRB) stock rose 4.1% in pre-market trading to $64 after H.C. Wainwright reiterated a Buy rating and $150 price target, citing positive FDA feedback on its TA-ERT therapy for Sanfilippo Syndrome Type B. The FDA endorsed the company's analytical strategies, supporting a planned BLA submission in Q4 2026. Analysts maintain a Strong Buy consensus with targets ranging from $104 to $230. The broader market's risk-on tone also contributed to the gain.

SPRUCE BIOSCIENCES, INC. (SPRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential

Wall Street analysts issued multiple rating changes. JPMorgan raised American Express (AXP) to Overweight, PT $400. Truist upgraded Biogen (BIIB) to Buy, PT $235, citing upcoming Phase 2 and Phase 3 readouts. JPMorgan also raised Keysight (KEYS) to Overweight, PT $400. Other actions included upgrades for Humana (HUM) and downgrades for Papa John’s (PZZA) and Best Buy (BBY).

HC Wainwright cut its price target for Spruce Biosciences (NASDAQ:SPRB) from $200 to $150 and kept a “buy” rating, according to a Monday research note cited by Benzinga. The target implies 192.57% upside versus the prior close. Other analysts cited include Oppenheimer “outperform” and Citizens JMP reducing its target to $150. Spruce reported ($8.94) EPS for the quarter on May 13, missing consensus ($7.93).

Jim Cramer advised against investing in AeroVironment (AVAV) despite a 40% stock drop, citing intense competition in the defense sector. The company reported record revenue of $1.98B for FY2026, up 141% YoY, driven by strong defense demand and a $464.8M U.S. Army contract. However, competition from firms like RTX and Lockheed Martin may pressure margins. Hedge fund interest grew, but short interest remains high at 9.55%.

ANI Pharmaceuticals (ANIP) appointed Henry Gosebruch to its board, replacing Muthusamy Shanmugam, who will remain in operational roles. Gosebruch has biotech leadership experience. The company, with a $1.6b market cap, develops and markets branded and generic drugs. Board changes may influence capital allocation and product mix.